Ann‐Charlotte Egnell

808 total citations
11 papers, 474 citations indexed

About

Ann‐Charlotte Egnell is a scholar working on Pharmacology, Molecular Biology and Genetics. According to data from OpenAlex, Ann‐Charlotte Egnell has authored 11 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 3 papers in Molecular Biology and 2 papers in Genetics. Recurrent topics in Ann‐Charlotte Egnell's work include Pharmacogenetics and Drug Metabolism (5 papers), Adenosine and Purinergic Signaling (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Ann‐Charlotte Egnell is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Adenosine and Purinergic Signaling (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Ann‐Charlotte Egnell collaborates with scholars based in Sweden, United Kingdom and United States. Ann‐Charlotte Egnell's co-authors include Brian Houston, Scott Boyer, Julia A. Hasler, Collen Masimirembwa, Tashinga E. Bapiro, Li‐Ming Gan, Cecilia Arfvidsson, Rainard Fuhr, Regina Fritsche‐Danielson and John L. Joyal and has published in prestigious journals such as Circulation, Nature Communications and Diabetes.

In The Last Decade

Ann‐Charlotte Egnell

11 papers receiving 452 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann‐Charlotte Egnell Sweden 8 218 182 96 87 33 11 474
Douglas Ferguson United Kingdom 14 185 0.8× 133 0.7× 142 1.5× 63 0.7× 19 0.6× 28 615
Bryan D. Marks United States 13 244 1.1× 138 0.8× 83 0.9× 60 0.7× 52 1.6× 17 442
Cathie Xiang United States 13 184 0.8× 152 0.8× 118 1.2× 38 0.4× 29 0.9× 17 572
María José Gómez Lechón Spain 4 153 0.7× 252 1.4× 154 1.6× 44 0.5× 14 0.4× 7 587
Stanley Roberts United States 13 202 0.9× 121 0.7× 127 1.3× 53 0.6× 18 0.5× 19 595
Daniel C. Kemp United States 9 179 0.8× 133 0.7× 124 1.3× 20 0.2× 63 1.9× 11 488
Dongping Ma United States 7 167 0.8× 142 0.8× 40 0.4× 64 0.7× 22 0.7× 15 338
Jessica E. Friedman United States 6 331 1.5× 59 0.3× 87 0.9× 78 0.9× 20 0.6× 7 625
Sue Zhou United States 9 117 0.5× 197 1.1× 98 1.0× 41 0.5× 13 0.4× 9 345
Archie Thurston United States 12 166 0.8× 72 0.4× 124 1.3× 24 0.3× 16 0.5× 18 496

Countries citing papers authored by Ann‐Charlotte Egnell

Since Specialization
Citations

This map shows the geographic impact of Ann‐Charlotte Egnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann‐Charlotte Egnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann‐Charlotte Egnell more than expected).

Fields of papers citing papers by Ann‐Charlotte Egnell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann‐Charlotte Egnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann‐Charlotte Egnell. The network helps show where Ann‐Charlotte Egnell may publish in the future.

Co-authorship network of co-authors of Ann‐Charlotte Egnell

This figure shows the co-authorship network connecting the top 25 collaborators of Ann‐Charlotte Egnell. A scholar is included among the top collaborators of Ann‐Charlotte Egnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann‐Charlotte Egnell. Ann‐Charlotte Egnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Egnell, Ann‐Charlotte, Magnus Åstrand, Samuel J. Daniels, et al.. (2024). Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo‐Controlled Study. Journal of the American Heart Association. 13(11). e033985–e033985. 1 indexed citations
2.
3.
Egnell, Ann‐Charlotte, Magnus Åstrand, Samuel J. Daniels, et al.. (2022). Abstract 13097: Safety, Pharmacokinetics, and Pharmacodynamics of AZD3366 Alone and in Combination With Aspirin and Ticagrelor in Healthy Subjects. Circulation. 146(Suppl_1). 1 indexed citations
4.
Gan, Li‐Ming, Maria Lagerström‐Fermér, Leif Carlsson, et al.. (2019). Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nature Communications. 10(1). 871–871. 152 indexed citations
5.
Abrahamsson, Kate, Patrik Andersson, Joakim Bergman, et al.. (2015). Discovery of AZD8165 – a clinical candidate from a novel series of neutral thrombin inhibitors. MedChemComm. 7(2). 272–281. 21 indexed citations
6.
Visser, Sandra A. G., Rhys D.O. Jones, Virna Schuck, et al.. (2013). Model-based drug discovery: implementation and impact. Drug Discovery Today. 18(15-16). 764–775. 46 indexed citations
7.
Egnell, Ann‐Charlotte, J. Brian Houston, & C. Scott Boyer. (2005). Predictive Models of CYP3A4 Heteroactivation: In Vitro-in Vivo Scaling and Pharmacophore Modeling. Journal of Pharmacology and Experimental Therapeutics. 312(3). 926–937. 28 indexed citations
8.
Egnell, Ann‐Charlotte, et al.. (2003). Generation and Evaluation of a CYP2C9 Heteroactivation Pharmacophore. Journal of Pharmacology and Experimental Therapeutics. 307(3). 878–887. 42 indexed citations
9.
Egnell, Ann‐Charlotte, Brian Houston, & Scott Boyer. (2003). In Vivo CYP3A4 Heteroactivation Is a Possible Mechanism for the Drug Interaction between Felbamate and Carbamazepine. Journal of Pharmacology and Experimental Therapeutics. 305(3). 1251–1262. 54 indexed citations
10.
Bapiro, Tashinga E., Ann‐Charlotte Egnell, Julia A. Hasler, & Collen Masimirembwa. (2001). Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.. PubMed. 29(1). 30–5. 85 indexed citations
11.
Olsson, Urban, Ann‐Charlotte Egnell, Mattias Lorentzon, et al.. (2001). Changes in Matrix Proteoglycans Induced by Insulin and Fatty Acids in Hepatic Cells May Contribute to Dyslipidemia of Insulin Resistance. Diabetes. 50(9). 2126–2132. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas Ferguson Breakdown of academic impact, for papers by Bryan D. Marks Breakdown of academic impact, for papers by Cathie Xiang Breakdown of academic impact, for papers by María José Gómez Lechón Breakdown of academic impact, for papers by Stanley Roberts Breakdown of academic impact, for papers by Daniel C. Kemp Breakdown of academic impact, for papers by Dongping Ma Breakdown of academic impact, for papers by Jessica E. Friedman Breakdown of academic impact, for papers by Sue Zhou Breakdown of academic impact, for papers by Archie Thurston
Rankless by CCL
2026